Siwen Hu-Lieskovan
( out of 94 reviews )

Siwen Hu-Lieskovan, PhD, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2C, Dermatology/Melanoma
Salt Lake City

  • Dr. Siwen Hu-Lieskovan is an Associate Professor of Medicine, and Director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute (HCI), University of Utah. She received her Hematology/Oncology Fellowship training at UCLA and held a faculty position there after fellowship prior to recruitment to HCI. She is a board-certified oncologist with clinical focus on melanoma/skin cancers and early phase testing of novel cancer immunotherapies in solid tumors. She is experienced with protocol development and conduct of immunotherapy-based clinical trials, and has been a principal investigator (PI) of industry-, investigator- and cooperative group-initiated clinical trials testing immune checkpoint inhibitors, oncolytic viruses, cancer vaccines and other immune-modulatory agents, as well as cell therapy with tumor infiltrating lymphocytes (TILs), genetically modified T cells and hematopoietic stem cells. Dr. Hu-Lieskovan is the physician lead of the melanoma/skin cancer Clinical Trial Research Group at the HCI Clinical Trial Office, and the institutional PI of SWOG trials at HCI. Nationally, she chairs the SWOG Immunotherapeutics Committee. She is a study chair and translational lead of several cross-NCTN protocols initiated by SWOG, including the immunoMATCH trial. She has been a scientific advisor on cancer immunotherapy drug development strategies for the pharmaceutical and biotechnology industry.

    Dr. Hu-Lieskovan is a physician scientist with research focus on characterization of tumor immune microenvironment, development of biomarkers to predict response and resistance to immunotherapies, and combination strategies to overcome immune resistance, by studying patient-derived clinical samples and immune-competent (syngeneic) animal models. In the past, she and her research teams made contributions in understanding the role of driver mutations in oncogenesis and immune evasion, mechanisms of response and resistance to immune checkpoint inhibitors, and developing novel drug delivery systems. She led the first studies showing efficacy of nanoparticle delivered siRNA targeting oncogenes in treating metastatic cancers, and synergistic effect of combining BRAF and MEK inhibitors with immunotherapy in BRAF mutant melanoma. She has authored/co-authored research articles, reviews, editorials and book chapters in peer-reviewed journals including Nature, Science Translational Medicine, Cell, New England Journal of Medicine, etc. She is a recipient of the prestigious National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award (CCITLA), American Society of Clinical Oncologist (ASCO) Young Investigator Award (YIA) and Career Development Award, the American Association for Cancer Research (AACR) Sharp Award, the Hope Foundation Dr. Coltman Award, the Melanoma Research Alliance YIA and Team Science Award, the Tower Research Foundation Award, the UCLA KL2 Translational Award, the Daniel Von Hoff Innovative Protocol Award, among others. Siwen has been a member of the NCI Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force, Society of ImmunoTherapy of Cancer (SITC) Biomarker Taskforce, ASCO, and AACR. She was an associate director of the UCLA Parker Institute of Cancer Immunotherapy supervising biobanking and translational studies, and previously served in the ASCO annual meeting Education Committee. She is currently serving in the ASCO Scientific Program Committee on the Melanoma/Skin Cancers Track.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.8 /5
    ( out of 94 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    February 22, 2025
    HUNTSMAN CANCER CENTER

    Dr. Hu was very patient, knowledgeable and respectful.

    February 13, 2025
    HUNTSMAN CANCER CENTER

    Thanks again! Great care

    January 02, 2025
    HUNTSMAN CANCER CENTER

    I've been trusting Dr Hu for many years

    December 26, 2024
    HUNTSMAN CANCER CENTER

    We appreciate your support, patients and dedication to this extremely important field of work. Thank you!

    November 14, 2024
    HUNTSMAN CANCER CENTER

    I had quite a history coming in to Huntsman she was aware of my path to the appointment.

    October 31, 2024
    HUNTSMAN CANCER CENTER

    She was very knowedgable and forthcoming. Expained what she thought was the proper course of treatment and why. Good experience!!

    October 18, 2024
    HUNTSMAN CANCER CENTER

    Waited more than 30 min for her come in

    October 17, 2024
    HUNTSMAN CANCER CENTER

    I feel so fortunate to have Dr. Hu-Lieskovan as my primary physician.

    October 10, 2024
    HUNTSMAN CANCER CENTER

    Amazing Doctor Cares for your well being.

    See More Patient Comments

  • Dr. Siwen Hu-Lieskovan is an Associate Professor of Medicine, and Director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute (HCI), University of Utah. She received her Hematology/Oncology Fellowship training at UCLA and held a faculty position there after fellowship prior to recruitment to HCI. She is a board-certified oncologist with clinical focus on melanoma/skin cancers and early phase testing of novel cancer immunotherapies in solid tumors. She is experienced with protocol development and conduct of immunotherapy-based clinical trials, and has been a principal investigator (PI) of industry-, investigator- and cooperative group-initiated clinical trials testing immune checkpoint inhibitors, oncolytic viruses, cancer vaccines and other immune-modulatory agents, as well as cell therapy with tumor infiltrating lymphocytes (TILs), genetically modified T cells and hematopoietic stem cells. Dr. Hu-Lieskovan is the physician lead of the melanoma/skin cancer Clinical Trial Research Group at the HCI Clinical Trial Office, and the institutional PI of SWOG trials at HCI. Nationally, she chairs the SWOG Immunotherapeutics Committee. She is a study chair and translational lead of several cross-NCTN protocols initiated by SWOG, including the immunoMATCH trial. She has been a scientific advisor on cancer immunotherapy drug development strategies for the pharmaceutical and biotechnology industry.

    Dr. Hu-Lieskovan is a physician scientist with research focus on characterization of tumor immune microenvironment, development of biomarkers to predict response and resistance to immunotherapies, and combination strategies to overcome immune resistance, by studying patient-derived clinical samples and immune-competent (syngeneic) animal models. In the past, she and her research teams made contributions in understanding the role of driver mutations in oncogenesis and immune evasion, mechanisms of response and resistance to immune checkpoint inhibitors, and developing novel drug delivery systems. She led the first studies showing efficacy of nanoparticle delivered siRNA targeting oncogenes in treating metastatic cancers, and synergistic effect of combining BRAF and MEK inhibitors with immunotherapy in BRAF mutant melanoma. She has authored/co-authored research articles, reviews, editorials and book chapters in peer-reviewed journals including Nature, Science Translational Medicine, Cell, New England Journal of Medicine, etc. She is a recipient of the prestigious National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award (CCITLA), American Society of Clinical Oncologist (ASCO) Young Investigator Award (YIA) and Career Development Award, the American Association for Cancer Research (AACR) Sharp Award, the Hope Foundation Dr. Coltman Award, the Melanoma Research Alliance YIA and Team Science Award, the Tower Research Foundation Award, the UCLA KL2 Translational Award, the Daniel Von Hoff Innovative Protocol Award, among others. Siwen has been a member of the NCI Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force, Society of ImmunoTherapy of Cancer (SITC) Biomarker Taskforce, ASCO, and AACR. She was an associate director of the UCLA Parker Institute of Cancer Immunotherapy supervising biobanking and translational studies, and previously served in the ASCO annual meeting Education Committee. She is currently serving in the ASCO Scientific Program Committee on the Melanoma/Skin Cancers Track.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - David Geffen School of Medicine, University of California Los Angeles Clinical Fellow
    Internship/Residency Internal Medicine - University of Southern California Intern/Resident
    Postdoctoral Fellowship Pathology - Children’s Hospital Los Angeles Postdoctoral Fellow
    Doctoral Training Pathobiology - Keck School of Medicine, University of Southern California Ph.D.
    Professional Medical Medicine - China Medical University M.D.

    Selected Publications

    Journal Article

    1. Fenlon J, Van Bibber N, Mahlow J, Yamoah K, Soupir AC, Nguyen JV, Moran Segura C, Spivak AM, Knudsen BS, Zhou Q, Hu-Lieskovan S, Puri S, Zhang W, DeRose YS, Suneja G, Coghill AE (2025). Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers. Cancer Epidemiol Biomarkers Prev.
    2. Fenlon J, Van Bibber N, Mahlow J, Yamoah K, Soupir AC, Nguyen JV, Moran Segura C, Spivak AM, Knudsen BS, Zhou Q, Hu-Lieskovan S, Puri S, Zhang W, DeRose YS, Suneja G, Coghill AE (2025). Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers. Cancer Epidemiol Biomarkers Prev. (Read full article)
    3. Li J, Al Faruque H, Li S, Sima M, Sborov D, Hu-Lieskovan S, Werner T, Kopeek J, Yang J (2025). PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer. J Control Release.
    4. Li J, Al Faruque H, Li S, Sima M, Sborov D, Hu-Lieskovan S, Werner T, Kopeek J, Yang J (2025). PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer. J Control Release, 382, 113682. (Read full article)
    5. Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles TL, Cannon DM, Haaland B, Schroeder JD, Nix DA, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S (2025). Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. Curr Oncol.
    6. Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles TL, Cannon DM, Haaland B, Schroeder JD, Nix DA, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S (2025). Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. Curr Oncol, 32(3). (Read full article)
    7. Marsiglio J, McPherson J, Wahl M, Hu-Lieskovan S (2024). Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature. Melanoma Res. (Read full article)
    8. Li J, Arnold J, Sima M, Al Faruque H, Galang J, Hu-Lieskovan S, Kopeek J, Yang J (2024). Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer. J Control Release, 376, 1014-1024. (Read full article)
    9. Woodford R, McKeown J, Hoeijmakers LL, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank CU, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson DB, Mcarthur GA, Rutkowski P, Neyns B, Sullivan RJ, Weber J, Carlino MS, Ascierto PA, Lo S, Long GV, Menzies AM (2024). Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. Eur J Cancer, 212, 115055. (Read full article)
    10. Woodford R, McKeown J, Hoeijmakers LL, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank CU, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson DB, Mcarthur GA, Rutkowski P, Neyns B, Sullivan RJ, Weber J, Carlino MS, Ascierto PA, Lo S, Long GV, Menzies AM (2024). Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. . Eur J Cancer.
    11. Fadlullah MZH, Lin CN, Coleman S, Young A, Naqash AR, Hu-Lieskovan S, Tan AC (2023). Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials. Oncologist, 29(5), 415-421. (Read full article)
    12. Fadlullah MZH, Lin CN, Coleman S, Young A, Naqash AR, Hu-Lieskovan S, Tan AC (2024). Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials. Oncologist, 29(5), 415-421.
    13. Chua KJ, Kronstedt S, Kaldany A, Srivastava A, Doppalapudi SK, Liu H, Tarhini AA, Gatti-Mays M, Gaughan E, Hu-Lieskovan S, Aljumaily R, Nepple K, Schneider B, Sterling J, Singer EA (2024). Comparing the rate of immunotherapy treatment change due to toxicity by sex. Cancer Rep (Hoboken), 7(2), e1932. (Read full article)
    14. Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, Natalia Sigal, Li-Chun Cheng, William D Chronister, Shane A Evans, John A Marsiglio, Berit Gibson, Yoko S Derose, Annaleah Larson, Carlos O Medina, Ramji Srinivasan, Matthew H Spitzer, Ngan Nguyen, John R Hyngstrom, Hu-Lieskovan S (2024). Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in checkpoint inhibitor-treated melanoma. J Immunother Cancer.
    15. Kovacsovics-Bankowski M, Sweere JM, Healy CP, Sigal N, Cheng LC, Chronister WD, Evans SA, Marsiglio J, Gibson B, Swami U, Erickson-Wayman A, McPherson JP, Derose YS, Eliason AL, Medina CO, Srinivasan R, Spitzer MH, Nguyen N, Hyngstrom J, Hu-Lieskovan S (2024). Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4(+) naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma. J Immunother Cancer, 12(1). (Read full article)
    16. Chua KJ, Kronstedt S, Kaldany A, Srivastava A, Doppalapudi SK, Liu H, Tarhini AA, Gatti-Mays M, Gaughan E, Hu-Lieskovan S, Aljumaily R, Nepple K, Schneider B, Sterling J, Singer EA (2024). Comparing the rate of immunotherapy treatment change due to toxicity by sex. . Cancer Rep (Hoboken).
    17. Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, ODwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH (2023). The New NCI Precision Medicine Trials. Clin Cancer Res, 29(23), 4728-4732. (Read full article)
    18. VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A (2023). Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med, 29(9), 2278-2285. (Read full article)
    19. Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Front Immunol.
    20. Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Front Immunol, 14, 1229823. (Read full article)
    21. VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A (2023). Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. . Nature Medicine.
    22. Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, ODwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH (2023). The New NCI Precision Medicine Trials. Clin Cancer Res.
    23. Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles T, Cannon DM, Haaland B, Schroeder JD, Nix D, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S (2023). Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis. Res Sq. (Read full article)
    24. Piper M, Kluger H, Ruppin E, Hu-Lieskovan S (2023). Immune Resistance Mechanisms and the Road to Personalized Immunotherapy. Am Soc Clin Oncol Educ Book, 43, e390290. (Read full article)
    25. Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A (2023). Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med, 388(9), 813-823. (Read full article)
    26. Yap T, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, Germaschewski F, Gliddon D, Stern O, Young L, Brewis N, Kayitalire L, Morrow M (2022). A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance. Clin Cancer Res.
    27. Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer, 10(10).
    28. Diab A, Hamid O, Thompson JA, Ros W, Eskens FALM, Doi T, Hu-Lieskovan S, Klempner SJ, Ganguly B, Fleener C, Wang X, Joh T, Liao K, Salek-Ardakani S, Taylor CT, Chou J, El-Khoueiry AB (2021). A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clin Cancer Res, 28(1), 71-83. (Read full article)
    29. Wang X, Haaland B, Hu-Lieskovan S, Colman H, Holmen SL (2021). First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Rep (Hoboken), 4(6), e1419. (Read full article)
    30. Hu-Lieskovan S, Braiteh F, Grilley-Olson JE, Wang X, Forgie A, Bonato V, Jacobs IA, Chou J, Johnson ML (2021). Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. Target Oncol, 16(6), 773-787. (Read full article)
    31. Diab A, Hamid O, Thompson J, Ros W, Eskens F, Doi T, Hu-Lieskovan S, Klempner S, Ganguly B, Fleener C, Wang X, Jo T, Liao K, Salek-Ardakani S, Taylor C, Chou J, El-Khoueiry A (2021). A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers. Clin Cancer Res.
    32. Pokorny R, McPherson JP, Haaland B, Grossmann KF, Luckett C, Voorhies BN, Sageser DS, Wallentine J, Tolman Z, Hu-Lieskovan S, Swami U (2021). Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. J Immunother Cancer.
    33. Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker HT (2020). SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. J Immunother Cancer, 8(2). (Read full article)
    34. Poran A, Scherer J, Bushway ME, Besada R, Balogh KN, Wanamaker A, Williams RG, Prabhakara J, Ott PA, Hu-Lieskovan S, Khondker ZS, Gaynor RB, Rooney MS, Srinivasan L (2020). Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell Rep Med, 1(8), 100141. (Read full article)
    35. Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L (2020). A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347-362.e24. (Read full article)
    36. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol, 156(9), 1004-1011. (Read full article)
    37. Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A (2020). Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discov, 10(8), 1140-1157. (Read full article)
    38. Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A (2022). Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer, 1(2), 264. (Read full article)
    39. Parisi G, Saco J, Salazar F, Tsoi J, Krystofinski P, Puig Saus C, Zhang R, Zhou J, Cheung-Lau G, Garcia AJ, Grasso CS, Tavar R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu A, Comin-Anduix B, Charych DH, Ribas A (Jan 2020). Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat Commun, 11(1), 660.
    40. Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A (2019). PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer, 1(1), 46-58. (Read full article)
    41. Abril-Rodriguez G, Torrejon T, Zaretsky J, Nowicki T, Tsoi J, Baselga Carretero I, Medina E, Quist M, Senapedis W, Baloglu E, Cheung-Lau G, Puig-Saus C, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Grasso C, Ribas A (Jan 2020). PAK4 inhibition reverses T cell exclusion in cancer and improves PD-1 blockade immunotherapy. Nat Cancer, 1, 46-58.
    42. Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (Nov 2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med.
    43. Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L (Oct 2019). Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell, 25(4), 542-557.e9.
    44. Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S (May 2019). Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. JAMA Oncol.
    45. Hu-Lieskovan S, Lisberg A, Zaretsky J, Wells D, Han M, Shintaku I, Wolf B, Abarca P, Slamon D, Goldman JW, Dubinett S, Ribas A, Garon EB (May 2019). Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer. Clin Cancer Res.
    46. Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS (May 2019). Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. J Immunother Cancer, 7(1), 119.
    47. Nowicki T, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran A, Grasso C, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A (Apr 2019). A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab. Clin Cancer Res, 25(7), 2096-2108.
    48. Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D (Oct 2018). Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proc Natl Acad Sci U S A.
    49. Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT (Jun 2018). Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. . Clin Cancer Res.
    50. Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski PE, Leiserson MD, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U (Mar 2018). Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov.
    51. Eroglu Z Zaretsky J Hu-Lieskovan S Kim DW, Algazi A, Johnson D, Liniker E, Kong B, Munhoz R, Rapisuwon S, Chmielowski B, Homet Moreno B, Cherry G, Berent-Maoz B, Comin-Anduix B, Wang X, Tumeh PC, Shintaku IP, Hugo W, Lo RS, Sosman JA, Joseph R, Postow M, Hwu W-J, Messina J, Long G, Ribas A Equal contribution as first authors, Corresponding authors (Jan 2018). High response to PD-1 blockadein desmoplastic melanoma. Nature, 553(7688), 347-350.
    52. Tolcher A, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQ (Jun 2017). Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab in patients with advanced solid tumors. Clin Cancer Res.
    53. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep, 19(6), 1189-1201.
    54. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Abril Rodriguez G, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A (Nov 2016). Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov.
    55. Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S Ribas A Corresponding Authors (Oct 2016). Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. Cancer Immunol Res, 4(10), 845-857.
    56. Zaretsky JM, Garcia Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Rodriguez GA, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez P, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher T, Lo RS, Ribas A (Sep 2016). Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med, 375(9), 819-29.
    57. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS (Mar 2016). Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 165(1), 35-44.
    58. Homet Moreno B, Mok S, Robert L, Comin-Anduix B, Hu-Lieskovan S, Ribas A (Aug 2015). Combined Treatment with Dabrafenib and Trametinib with Immune-stimulating Antibodies for BRAF Mutant Melanoma. Oncoimmunology, 5(7), e1052212.
    59. Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A (May 2015). Inhibition of CSF-1R Improves Antitumor Efficacy of BRAF Inhibition. BMC Cancer, 15(1), 356.
    60. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Koya KC, Graeber T, Comin-Anduix B, Ribas A (Mar 2015). Improved Antitumor Activity of Immunotherapy with BRAF and MEK inhibitors in BRAFV600E mutant melanoma. Sci Transl Med, 7(279), 279.
    61. Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hlscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rdel C, Bracko M, Velenik V, Lenz HJ (Aug 2011). EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. . Clin Cancer Res, 17(15), 5161-9.
    62. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (Jan 2011). A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol, 22(1), 104-9.
    63. Zwerner P, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May WA (May 2008). The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene, 27(23), 3282-91.
    64. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (Oct 2005). Sequence-specific knockdown of EWS-FLI1 by targeted, non-viral delivery of siRNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res, 65(19), 8984-8992.
    65. Popielarski SR, Hu-Lieskovan S, French SW, Triche TJ, Davis ME (Aug 2005). A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug Chem, 16(5), 1071-80.
    66. Hu-Lieskovan S, Zhang J, Schofield DE, Shimada H, Wu L, Triche TJ (Jun 2005). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing’s family of tumors. Cancer Res, 65(11), 4633-44.
    67. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (Dec 2004). Lack of interferon response in animals to naked siRNAs. Nat Biotechnol, 22(12), 1579-82.
    68. Zhang J, Hu S, Schofield D, Sorensen P, Triche TJ (Sep 2004). Selective usage of D type cyclins by Ewing's tumors and rhabdomyosarcomas. Oncogene, 64(17), 6026-34.

    Review

    1. Sankar K, Ye JC, Li Z, Zheng L, Song W, Hu-Lieskovan S (2022). The role of biomarkers in personalized immunotherapy. [Review]. Biomark Res, 10(1), 32. (Read full article)
    2. Yuan J, Khilnani A, Brody J, Andtbacka RHI, Hu-Lieskovan S, Luke JJ, Diab A, Marabelle A, Snyder A, Cao ZA, Hodi FS (2021). Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. [Review]. Eur J Cancer, 157, 493-510. (Read full article)
    3. Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U (2020). The dark side of immunotherapy. [Review]. Ann Transl Med, 9(12), 1041. (Read full article)
    4. Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Johnson ML (2021). Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need. [Review]. Future Oncol, 17(11), 1401-1439. (Read full article)
    5. Moser J, Hu-Lieskovan S (Apr 2020). Mechanisms of Resistance to PD-1 Checkpoint Blockade. [Review]. Drugs, 80(5), 459-465.
    6. Davda J, Declerck P, Hu-Lieskovan S, Hickling T, Jacobs I, Chou J, Salek-Ardakani S, Kraynov E (April 2019). Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. [Review]. J Immunother Cancer, 7, Article: 105.
    7. Nowicki T, Hu-Lieskovan S, Ribas A (Jan/Feb 2018). Mechanisms of Resistance to PD-1 and PD-L1 blockade. [Review]. Cancer J, 24(1), 47-53.
    8. Sharma P, Hu-Lieskovan S, Wargo J, Ribas A (February 2017). Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. [Review]. Cell, 168(4), 707-723.
    9. Hu-Lieskovan S, Ribas R (Jan/Feb 2017). New combination strategies using PD-1/ L1 checkpoint inhibitors as a backbone. [Review]. Cancer J, 23(1), 10-22.
    10. Ribas A, Hu-Lieskovan S (November 2016). What does PD-L1 positive or negative tumors mean? Perspective for Clinical Correlates of Immunotherapy. [Review]. J Exp Med, 213(13), 2835-2840.
    11. Robert L, Ribas A, Hu-Lieskovan S (February 2016). Combining targeted therapy with immunotherapy. Can 1 + 1 equal more than 2? [Review]. Semin Immunol, 28(1), 73-80.
    12. Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A (July 2014). Combining targeted therapy with immunotherapy in BRAF mutant melanoma: promise and challenges. [Review]. J Clin Oncol, 32(21), 2248-2254.

    Book Chapter

    1. Piper M, Kluger H, Ruppin E, Hu-Lieskovan S (2023). Immune Resistance Mechanisms and the Road to Personalized Immunotherapy. In Am Soc Clin Oncol Educ Book.
    2. McKean W, Moser J, Rimm D, Hu-Lieskovan S (2020). Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. In ASCO Educational Book 40 (2020) (pp. e275-e291).
    3. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S (Jan 2019). Mechanisms of Resistance to Immune Checkpoint Blockade: Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients? In ASCO Educational Book 39 (2019) (pp. 147-164).
    4. Hu-Lieskovan S, Chmielowski B, Ribas A (2017). Cancer Immunotherapy. In Chmielowski B, Territo MC (Eds.), Manual of Clinical Oncology (Eighth Edition). Lippincott Williams & Wilkins.
    5. Sharma S, Hu-Lieskovan S, Dubinett SM, Moon Lee J (2015). Addressing inflammation with immunotherapy. In Dubinett S (Ed.), Inflammation and Lung Cancer (Second Edition). New York: Springer.

    Commentary

    1. McKean W, Hu-Lieskovan S (2021). Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection. . ASCO Daily News.

    Editorial

    1. Pal S, Hu-Lieskovan S, Agarwal N (Sep 2019). Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours? 20(11), 1473-1474.
    2. Hu-Lieskovan S, Homet Moreno B, Ribas A (June 2018). Excluding T cells: Is β-catenin the full story? 27(6), 749-750.

    Letter

    1. Liu M, Wang X, Du X, Zhang Y, Ai C, Hu-Lieskovan S, Li T, Devenport M, Liu Y, Zheng P (2022). CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect. [Letter to the editor]. Signal Transduct Target Ther, 7(1), 224. (Read full article)

    Abstract

    1. Hu-Lieskovan S, Kari Kendra, Kai He, Bently Doonan, Eric Schaefer, Edward Arrowsmith, Ki Chung, Eric Whitman, Ulka Vaishampayan, Svetlana Shpyro, Karrie Wang, Juanjuan Su, Chris Leung, Kazu Kai, Yang Liu, Pan Zheng, Tianhong Li (2025). Gotistobart in combination with pembrolizumab in patients with advanced melanoma who have progressed on PD-1 inhibitors with or without CTLA-4 inhibitors. ASCO 2025 [Abstract].

    Video/Film/CD/Web/Podcast

    1. Hu-Lieskovan S, Ribas A (2013). ASCO 2013 Highlights: Melanoma (review) [Web]. Available: Oncofacts.com.

    Research Lab

    Lab link

  • News & Podcasts

    Huntsman Cancer Institute News